Screener
Regenxbio RGNX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $108.02M+406% | $6.39M-92.8% | $30.34M+43.0% | $29.73M+22.9% | $21.36M-4.2% | ||
| $56.09M-5.7% | $57.34M+8.0% | $59.61M+18.3% | $56.1M+3.1% | $59.5M+21.8% | ||
| $21.62M+8.7% | $21.31M+4.7% | $22.38M+11.6% | $20.25M+4.3% | $19.88M+5.5% | ||
| $78.76M-6.9% | $89.76M+16.7% | $87.97M+21.2% | $82.14M-4.8% | $84.64M+8.0% | ||
| $29.26M+146% | -$83.36M-787% | -$57.64M-12.2% | -$52.41M+15.6% | -$63.28M-12.9% | ||
| 27.1%+323pp | -1,304%-1,318pp | -190%+52.2pp | -176.3%+80.3pp | -296.3%-44.9pp | ||
| $7.79M-29.1% | $8.71M+1.6% | $12.28M+30.4% | $13.17M+1,506% | $10.99M+2,348% | ||
| -$6.55M+13.7% | -$6.69M-10.7% | -$9.51M-5,327% | -$9.53M-484% | -$7.59M-349% | ||
| $22.71M+132% | -$90.05M-1,580% | -$67.15M-31.2% | -$61.94M-3.9% | -$70.87M-33.7% | ||
| 21%+353pp | -1,408.6%-1,415pp | -221.3%+19.9pp | -208.3%+38.0pp | -331.8%-94.1pp | ||
| $0.43+131% | -$1.72-1,533% | -$1.30-30.0% | -$1.20-2.6% | -$1.38-31.4% | ||
| $33.02M+156% | -$79.51M-594% | -$53.77M-13.6% | -$48.53M+16.5% | -$59.37M-14.2% | ||
| 30.6%+309pp | -1,243.6%-1,262pp | -177.2%+45.9pp | -163.2%+77.0pp | -278%-44.8pp | ||
| $29.26M+146% | -$83.36M-787% | -$57.64M-12.2% | -$52.41M+15.6% | -$63.28M-12.9% |
FAQ
- What is Regenxbio's revenue?
- Regenxbio (RGNX) generated $174.5M in revenue over the trailing twelve months, up 12.0% year over year.
- Is Regenxbio profitable?
- Regenxbio is not currently profitable: it reported a net loss of $196.4M over the trailing twelve months, a -112.6% net margin.
- What are Regenxbio's profit margins?
- Gross margin is 59.7% and operating margin is -94.1%, with a -112.6% net margin.
- What is Regenxbio's earnings per share?
- Regenxbio's diluted EPS over the trailing twelve months is $-3.79.
- Where does Regenxbio's income statement data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
